EZH2抑制剂增强STING激动剂诱导的黑色素瘤抗肿瘤免疫
该研究探讨黑色素瘤中STING表达被表观遗传抑制的机制。研究发现H3K27me3抑制STING表达,EZH2抑制剂可诱导H3K27从三甲基化向乙酰化转变,增加STING表达。STING激动剂与EZH2抑制剂联用上调MHC I类和趋化因子,在B16-F10小鼠模型中协同抑制肿瘤生长并增加CD8+ T细胞浸润。
要点
- 黑色素瘤中STING表达受H3K27me3表观遗传抑制。
- EZH2抑制剂可增加STING表达并增强STING激动剂效果。
- 两药联用在B16-F10模型中协同抑制肿瘤并增加CD8+ T细胞浸润。
核心结论
- 黑色素瘤中STING表达受H3K27me3表观遗传抑制,EZH2抑制剂可逆转该抑制。
- STING激动剂与EZH2抑制剂联用可增强抗肿瘤免疫反应,可能成为难治性黑色素瘤的治疗选择。
研究设计与样本
- 研究为实验性研究,使用黑色素瘤细胞和小鼠模型B16-F10。
主要发现
- STING表达在黑色素瘤中受H3K27me3表观遗传抑制。
- EZH2抑制剂诱导H3K27从三甲基化向乙酰化转变,增加STING表达。
- STING激动剂与EZH2抑制剂联用上调MHC I类表达和趋化因子产生。
- 全转录组分析显示联合治疗组IFN-1相关基因显著上调。
- 联合治疗在免疫原性差的黑色素瘤小鼠模型B16-F10中协同减少肿瘤生长并增加CD8+ T细胞浸润。
临床怎么用
- 对于当前免疫治疗难治的黑色素瘤患者,STING激动剂与EZH2抑制剂联用可能是一种有前景的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STING agonists are a new class of drugs for cancer immunotherapy that activate both innate and adaptive antitumor immunity. Recently, multiple clinical trials of STING agonists have been conducted in hematological malignancies and solid tumors. However, STING is commonly suppressed in melanoma through mechanisms that remain unclear. We found that STING expression was epigenetically suppressed by H3K27me3 in melanoma, and EZH2 inhibitor could induce an H3K27 shift from trimethylation to acetylation, resulting in increased expression of STING. Furthermore, a combination of STING agonist and EZH2 inhibitor upregulated major histocompatibility complex class I expression and chemokine production. Whole-transcriptome analysis showed that IFN-1‒related genes were significantly upregulated in the combination treatment group. In addition, the combination treatment synergistically reduced tumor growth and increased CD8+ T-cell infiltration in a poorly immunogenic melanoma mouse model B16-F10. These results showed, to our knowledge, a previously unreported mechanism underlying the epigenetic regulation of STING expression in melanoma; a combination of STING agonists and EZH2 inhibitors can boost the antitumor immune response and would be a promising treatment option for patients with melanoma who are refractory to current immunotherapies.
引用
- Xu T, Dai J, Tang L, et al. EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma. J Invest Dermatol. 2021. PMID: 34571002. doi:10.1016/j.jid.2021.08.437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。